Literature DB >> 14657069

Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer.

Loïc Le Marchand1, Ann Seifried, Annette Lum-Jones, Timothy Donlon, Lynne R Wilkens.   

Abstract

CONTEXT: Cyclin D1 (CCND1) is a key cell cycle regulatory protein, the overexpression of which is often found in human tumors and is associated with cell proliferation and poor prognosis. A common adenine-to-guanine substitution polymorphism (A870G) in the CCND1 gene results in an altered messenger RNA transcript and a longer-life protein, which are preferentially encoded by the A allele.
OBJECTIVE: To test the overall and stage-specific associations of the CCND1 870A allele with colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: A population-based case-control study conducted in the multiethnic population of Hawaii between January 1, 1994, and August 31, 1998, which included 504 patients with incident colorectal cancer and 624 population-based participants of Japanese, white, or Native Hawaiian origin. Participation rates were 58% for cases and 52% for controls. Main Outcome Measurement Ethnicity, gene-dosage effects, and stage (regional/distant) and subsite (colon vs rectal) of cancer.
RESULTS: The odds ratio (OR) for the CCND1 870 GA and AA genotypes compared with the GG genotype was 1.2 (95% confidence interval [CI], 0.9-1.7) and 1.5 (95% CI, 1.0-2.1), respectively (P =.03 for gene-dosage effect). These risk estimates were significantly greater for patients diagnosed at a regional or distant stage (GA vs GG: OR, 1.7; 95% CI, 1.1-2.5 and AA vs GG: OR, 1.9; 95% CI, 1.2-3.1; P =.008 for gene-dosage effect) compared with those estimates for patients diagnosed at an earlier stage (P =.048). In subset analyses, the association between the A allele and advanced colorectal cancer was statistically significant in white and Hawaiian participants but not in Japanese, and was stronger for rectal cancer.
CONCLUSION: The CCND1 870A allele may be associated with colorectal cancer, and particularly with forms of the disease that result in severe morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657069     DOI: 10.1001/jama.290.21.2843

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  30 in total

1.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

2.  Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population.

Authors:  Jing Jiang; Jingweng Wang; Sadao Suzuki; Vendhan Gajalakshmi; Kiyonori Kuriki; Yang Zhao; Seiichi Nakamura; Susumu Akasaka; Hideki Ishikawa; Shinkan Tokudome
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-03       Impact factor: 4.553

Review 3.  Regulation of chemoresistance via alternative messenger RNA splicing.

Authors:  Scott T Eblen
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

4.  Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.

Authors:  Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

5.  Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions.

Authors:  Yuanqing Ye; Scott M Lippman; J Jack Lee; Meng Chen; Marsha L Frazier; Margaret R Spitz; Xifeng Wu
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

6.  Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Mol Cancer       Date:  2009-11-02       Impact factor: 27.401

7.  BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.

Authors:  Z Saridaki; D Papadatos-Pastos; M Tzardi; D Mavroudis; E Bairaktari; H Arvanity; E Stathopoulos; V Georgoulias; J Souglakos
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

8.  Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population.

Authors:  Zhangyong Hu; Zhipeng Zhou; Guolian Xiong; Yali Wang; Yi Lai; Lan Deng; Jinliang Yang
Journal:  Tumour Biol       Date:  2014-02-26

9.  Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Authors:  Vanita K Gupta; Andrew Feber; Liqiang Xi; Arjun Pennathur; Maoxin Wu; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 10.  Nuclear receptor coregulators in cancer biology.

Authors:  Bert W O'Malley; Rakesh Kumar
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.